Schuhmacher Bianca, Rengstl Benjamin, Döring Claudia, Bein Julia, Newrzela Sebastian, Brunnberg Uta, Kvasnicka Hans Michael, Vornanen Martine, Küppers Ralf, Hansmann Martin-Leo, Hartmann Sylvia
Dr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany.
Department of Internal Medicine 2, Hospital of the J. W. Goethe University, Frankfurt am Main, Germany.
Oncotarget. 2016 Nov 1;7(44):72197-72210. doi: 10.18632/oncotarget.12363.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an explanation for the relatively low tumor cell content. Moreover, the findings suggest that treatment of these patients with immune checkpoint inhibitors may enhance an already ongoing host response in these patients.
结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)是一种惰性淋巴瘤,但可转化为弥漫性大B细胞淋巴瘤(DLBCL),表现出更具侵袭性的临床行为。在分子水平上,对这些病例了解甚少。因此,本研究的目的是通过基因表达谱(GEP)对由NLPHL转化而来的DLBCL(LP-DLBCL)进行特征描述。GEP揭示了一种指向特定宿主反应的炎症特征。在一个类似于这种宿主反应的共培养模型中,DEV肿瘤细胞表现出生长行为受损。肿瘤细胞增殖减少所涉及的机制包括MYC及其靶基因的下调。通过免疫组织化学在12/16例LP-DLBCL中也证实了MYC表达的缺失。此外,DEV肿瘤细胞在与T细胞或单核细胞共培养后,CD274/PD-L1上调,其表达在12/19例LP-DLBCL中得到验证。因此,我们的数据为LP-DLBCL的发病机制提供了新的见解,并解释了肿瘤细胞含量相对较低的原因。此外,研究结果表明,用免疫检查点抑制剂治疗这些患者可能会增强这些患者中已经存在的宿主反应。